SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NexStar Pharm(NXTR)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Joe Wesley who wrote (233)10/31/1997 7:46:00 PM
From: Miljenko Zuanic  Read Replies (1) of 328
 
Hi Amateur:

Glad that somebody share similar view on NXTR. On the other hand, *major broker* (?) is bearish and they lowered 98 EPS from 0.57 to 0.09 and downgrade NXTR to market perform rating.

I think that investors are still uncertain regards AmBisome US revenue because it compete with two other liposomal products. Many forgot that main competitor is Amphotericin B (not Abelcet and/or Amphotec), and company need to prove that there are difinitly benefit (therapeutic and cost base) for liposomal formulation versus free drug. In US Fujisawa/NXTR will tried to confirm this *facts* with P IV trial.

mz
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News